Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues].

Itaru Ozeki, Shuhei Hige, Yoshiyasu Karino, Mutsuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takumi Ohmura, Takahiro Sato, Joji Toyota

Department of Gastroenterology, Sapporo Kosei General Hospital. i.ozeki@ja-hokkaidoukouseiren.or.jp

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2013 Jan

filter terms:

In 18 of 547 patients who had received nucleoside analogue preparations for 1 year or more, multi-drug resistance was detected, after a median follow-up of 53 months. No patient showed liver failure related to multi-drug resistance acquisition. Multi-drug resistance was associated with entecavir (ETV) therapy in 7 lamivudine (LAM) -resistant patients, combination therapy with adefovir dipivoxil (ADV) in 8 LAM-resistant patients, LAM switching to ETV in 2 patients, and initial ETV administration in 1. For treatment, combination therapy with LAM and ADV was performed. In non-responders, combination therapy with ADV and ETV was employed. In all LAM- and ADV-resistant patients, and the HBV DNA level decreased to 3.0LC/ml or less. However, a similar decrease was noted in 7 (58.3%) of 12 LAM- and ETV-resistant patients. Of the 18 patients, 1 did not respond to combination therapy with ADV and ETV. Therapy with tenofovir disoproxil fumarate (TDF) was required.

Citation

Itaru Ozeki, Shuhei Hige, Yoshiyasu Karino, Mutsuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takumi Ohmura, Takahiro Sato, Joji Toyota. Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 2013 Jan;110(1):44-55